

NeuroMetrix Consummates One-for-Four Reverse Split

Shares of Common Stock and Listed Warrants Have Begun Trading on a Split-Adjusted Basis on The NASDAQ Capital Market

BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today confirmed that it has consummated a one-for-four reverse split of its common stock.

Following the one-for-four reverse split, the Company's common stock began trading on the NASDAQ Capital Market on a split-adjusted basis with the opening of the markets on Wednesday, December 2, 2015, under new CUSIP number 641255500. Additionally, the Company's warrants to purchase common stock that are listed on the NASDAQ Capital Market (the "Listed Warrants") also began trading on a split-adjusted basis with the opening of the markets on Wednesday, December 2, 2015, under new CUSIP number 641255153. Following the split, each Listed Warrant and underlying share of common stock was divided by a factor of four and the exercise price was increased by a factor of four from \$1.25 to \$5.00. Accordingly, four pre-split Listed Warrants are now required to exercise one share of common stock at an exercise price of \$5.00 per share. Shares of the Company's common stock and the Company's Listed Warrants to purchase common stock will continue to trade under the symbols "NURO" and "NUROW". Immediately subsequent to the reverse stock split, there were approximately 3,446,310 shares of the Company's common shares issued and outstanding and approximately 3,638,250 Listed Warrants to purchase 3,638,250 shares of common stock at an exercise price of \$5.00.

For more information regarding the Company's reverse stock split, please refer to the proxy statement filed by the Company with the Securities and Exchange Commission on Schedule 14A on September 29, 2015.

About NeuroMetrix

NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

View source version on <u>businesswire.com</u>: <u>http://www.businesswire.com/news/home/20151202006285/en/</u>

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media